Rhythm Pharmaceuticals (RYTM) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is RYTM's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

� 2025 Benzinga.com. Benzinga does not provide investment advice.…

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) on Monday presented two-year Phase 3 setmelanotide results and global diagnostic criteria at ObesityWeek 2026, highlighting sustained weight reductions and earlier diagnosis for …

– Two-year results from Phase 3 TRANSCEND trial showed continuous setmelanotide therapy sustained BMI reductions in patients with acquired hypothalamic obesity –…

Senti Biosciences (NASDAQ: SNTI - Get Free Report) and Rhythm Pharmaceuticals (NASDAQ: RYTM - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based o…

Rhythm Pharmaceuticals maintains strong commercial momentum, with IMCIVREE sales up 79.5% YoY and a broadening prescriber base in the acquired HO. RYTM's valuation is elevated at 27.4x trailing sales, reflecting high exp…

AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.…

-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome -- BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM…

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript…

Rhythm Pharmaceuticals NASDAQ: RYTM reported third-quarter global net product sales of $92.1 million, up 29% sequentially, as the company cited a strong early U.S. launch for IMCIVREE in acquired hypothalamic obesity, or…

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.82 per share a year ago.…

-- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026 net product revenue …

-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed payment…

Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twenty-two ratings firms that are covering the stock, MarketBeat.com reports. One r…

BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine dis…

-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living w…

Rhythm Pharmaceuticals (RYTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.…

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) breached their fiduciary…

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine di…

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) CEO David Meeker sold 50,000 shares of the company's stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price …

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM - Get Free Report) traded down 5.3% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $97.67 and last traded at $97.035…

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated improvements across…

Bank of New York Mellon Corp acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acq…

-- Approximately 5,000 to 8,000 patients estimated to be living with acquired HO in Japan -- -- Commercial launch in Japan expected by end of 2026, pending final pricing determination --…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

